COBRE-DIABETES

糖尿病

• 批准号: 10399857
• 负责人: MARIANA GERSCHENSON
• 金额: $ 23.18万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10399857
• 关键词: Acute; Address; Administrative Supplement; Animals; Bioluminescence; Blood; Blood Volume; Blood gas; Centers of Research Excellence; Chemistry; Clinical; Contract Services; Core Facility; Diabetes Mellitus; Diagnosis; Dose; Electrolytes; Equipment; Evaluation; Fluorescence; Fostering; Funding; Funding Opportunities; Goals; Growth; Hawaii; Hematocrit procedure; Hemoglobin; Individual; Infrastructure; Investigation; Longitudinal Studies; Metabolic; Minority Groups; Modernization; Mus; National Institute of General Medical Sciences; Phase; Population; Prevention; Renal function; Research; Research Personnel; Resources; Roentgen Rays; Services; System; Technology; Testing; Universities; Vision; career development; cost; equipment acquisition; health disparity; imaging system; improved; in vivo; in vivo imaging system; medical schools; operation; rapid test; response

PROJECT SUMMARY/ABSTRACT This application is for a supplement to support a Phase I Center of Biomedical Research Excellence (COBRE) at the University of Hawaii (UH) on Diabetes (1P20GM113134-04) in response to funding opportunity NOT- GM-21-029, “Administrative Supplements for Equipment Purchases for NIGMS-funded Center and Core Facilities”. The COBRE-Diabetes has developed a Resource Core dedicated to supporting career development for young investigators and to foster diabetes-related research in the state, which is acutely needed. It is estimated that a third of the State’s population will be living with diabetes by the year 2050. The COBRE-Diabetes Resource Core goal is to establish a new and easily accessible modern infrastructure to support investigations in the mechanisms, diagnosis, prevention, and/or treatment of diabetes to address health disparities in the minority populations in Hawaii. Our unique aim is to Maintain the growth and enhance the sustainability of Resource Core. With this proposal, we will optimize our core capacity in order to continue capacity improvement that has been successfully initiated in the first Phase of COBRE-Diabetes funding. In order to accomplish this objective, we request funding for the acquisition of two new pieces of equipment. We hope to replace an existing obsolete Xenogen Vivo Vision IVIS Lumina Imaging system with an IVIS Lumina XRMS in vivo imaging system. This is equipment offers cutting edge in vivo fluorescence and bioluminescence technology combined with low dose 2D X-ray allowing for non-invasive and precise metabolic analyses. This will give us an expanded capacity with multiple animals to perform longitudinal studies. The second equipment is an i-STAT clinical blood analyzer that operates with the advanced technology of single- use i-STAT test cartridges offering a wide array of tests on a single platform, including rapid tests for electrolytes, chemistries, blood gases, hematocrit and hemoglobin or the fast evaluation of metabolic status and renal function. This system uses minimal blood volumes, which will not require animal (mouse) sacrifice. Blood analyses are currently done using individual and dedicated kits that is laborious or contracting services outside of the University. There are many projects ongoing in the DRC that can best be performed in Hawaii. Our distance from US mainland requires that we develop a fundamental repertoire of Core services for diabetes research with COBRE resources. The Dean of the Medical School has committed to provide institutional support to cover the cost of operation for three years after the purchase of these equipment.

项目摘要/摘要 该应用程序是为了支持I阶段生物医学研究卓越中心（Cobre）的补充 在夏威夷大学（UH）的糖尿病（1P20GM113134-04），以回应资金机会 GM-21-029，“用于NIGMS资助的中心和核心的设备购买的行政补品 设施。 对于年轻的研究人员，并促进该州与糖尿病相关的研究，这是急需的。这是 据估计，到2050年，该州的三分之一人口将患有糖尿病。 cobre-Diabetes资源核心目标是建立一个新的易于访问的现代基础设施 支持糖尿病的机制，诊断，预防和/或治疗的研究 夏威夷少数族裔人口的健康差异。我们的独特目的是保持增长和 增强资源核心的可持续性。通过此提案，我们将按顺序优化我们的核心能力 继续提高能力的提高，并在cobre-Diabetes的第一阶段成功启动 资金。为了实现这一目标，我们要求资金用于收购两个新部分 设备。我们希望用 IVIS Lumina XRMS中的体内成像系统。这是设备在体内荧光内提供最前沿 生物发光技术与低剂量的2D X射线结合使用，可以进行非侵入性和精确的代谢 分析。这将使我们能够通过多个动物进行纵向研究的能力扩大。 第二个设备是I-Stat临床血液分析仪，可使用单一的先进技术运行 使用I-STAT测试弹药筒在单个平台上提供各种测试，包括快速测试 电解质，化学，血气，血细胞比容和血红蛋白或代谢状态的快速评估 和肾功能。该系统使用最少的血液量，这不需要动物（小鼠）牺牲。 目前，使用实验室或承包服务的个人和专用套件进行血液分析 在大学外。刚果民主共和国正在进行的许多项目都可以在夏威夷进行。 我们与我们大陆的距离要求我们为核心服务的基本曲目供 糖尿病研究具有毛关系。医学院的院长致力于提供 购买这些设备后三年的机构支持以支付运营成本。

项目成果

Bicuspid and unicuspid aortic valves: Different phenotypes of the same disease? Insight from the GenTAC Registry.

二叶式和单叶式主动脉瓣：同一疾病的不同表型？

• DOI: 10.1111/chd.12520
• 发表时间: 2017
• 期刊: Congenital heart disease
• 影响因子: 0.3
• 作者: Krepp,JosephM;Roman,MaryJ;Devereux,RichardB;Bruce,Adrienne;Prakash,SiddharthK;Morris,ShaineA;Milewicz,DiannaM;Holmes,KathrynW;Ravekes,William;Shohet,RalphV;Pyeritz,ReedE;Maslen,CherylL;Kroner,BarbaraL;Eagle,KimA;Pre
• 通讯作者: Pre

The Role of Ferroptosis in Adverse Left Ventricular Remodeling Following Acute Myocardial Infarction.

• DOI: 10.3390/cells11091399
• 发表时间: 2022-04-20
• 期刊: CELLS
• 影响因子: 6
• 作者: Komai, Kyoko;Kawasaki, Nicholas K.;Higa, Jason K.;Matsui, Takashi
• 通讯作者: Matsui, Takashi

The effects of Tel2 on cardiomyocyte survival.

Tel2 对心肌细胞存活的影响。

• DOI: 10.1016/j.lfs.2019.116665
• 发表时间: 2019
• 期刊: Life sciences
• 影响因子: 6.1
• 作者: Yorichika,Naaiko;Baba,Yuichi;Shimada,BrianaK;Thakore,Manoj;Wong,SharonM;Kobayashi,Motoi;Higa,JasonK;Matsui,Takashi
• 通讯作者: Matsui,Takashi

Associations of FGF21 and GDF15 with mitochondrial dysfunction in children living with perinatally-acquired HIV: A cross-sectional evaluation of pediatric AIDS clinical trials group 219/219C.

• DOI: 10.1371/journal.pone.0261563
• 发表时间: 2021
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Gojanovich GS;Jacobson DL;Broadwell C;Karalius B;Kirmse B;Geffner ME;Jao J;Van Dyke RB;McFarland EJ;Silio M;Crain M;Gerschenson M;Pediatric HIV/AIDS Cohort Study
• 通讯作者: Pediatric HIV/AIDS Cohort Study

Pathogenic variants in the ABCC6 gene are associated with an increased risk for ischemic stroke.

• DOI: 10.1111/bpa.12620
• 发表时间: 2018-11
• 期刊: Brain pathology (Zurich, Switzerland)
• 作者: De Vilder EYG;Cardoen S;Hosen MJ;Le Saux O;De Zaeytijd J;Leroy BP;De Reuck J;Coucke PJ;De Paepe A;Hemelsoet D;Vanakker OM
• 通讯作者: Vanakker OM